TechNavio's analysts forecast the Global Generic Drugs market to grow at a CAGR of 11.02 percent over the period 2013-2018. The patent expiry of top-selling drugs is one of the major drivers contributing to the growth of this market. The market is also witnessing an increase in mergers and acquistions. However, intense competition among vendors could squeeze profit margins, increase pricing pressure, and pose a challenge to the growth of this market.
TechNavio's report, the Global Generic Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas, and the EMEA and APAC regions; it also covers the Global Generic Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space include Actavis plc, Mylan Inc., Novartis International AG (Sandoz), STADA Arzneimittel AG, and Teva Pharmaceutical Industries Ltd.
Other vendors mentioned in the report are 3SBio Inc., Amgen Inc., Apotex Inc., AstraZeneca plc, Aurobindo Pharma Ltd., Baxter International Inc., Berlin-Chemie AG, Biocon Ltd., Biogen Idec Inc., Boehringer Ingelheim GmbH, Celltrion Inc., Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Dr. Reddys Laboratories Ltd., Emcure Pharmaceuticals Ltd., Gedeon Richter plc, GlaxoSmithKline plc, Hospira Inc., Impax Laboratories Inc., Intas Pharmaceuticals Ltd., Lupin Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Par Pharmaceutical Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Roche Holding AG, Sanofi S.A., Wockhardt Ltd., and Zydus Cadila Healthcare Ltd.
Key questions answered in this report:
What will the market size and growth rate be in 2018?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by key vendors?
What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of our analysts time when you purchase this market report. Details provided within the report.
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Generic Drugs Market in the US
06.3.1 Market Size and Forecast
06.4 Generic Drugs Market in Europe
06.4.1 Market Size and Forecast
06.5 Generic Drugs Market in Germany
06.5.1 Market Size and Forecast
06.6 Generic Drugs Market in the UK
06.6.1 Market Size and Forecast
06.7 Generic Drugs Market in Italy
06.7.1 Market Size and Forecast
06.8 Generic Drugs Market in France
06.8.1 Market Size and Forecast
06.9 Generic Drugs Market in Spain
06.9.1 Market Size and Forecast
06.10 Generic Drugs Market in China
06.10.1 Market Size and Forecast
06.11 Generic Drugs Market in India
06.11.1 Market Size and Forecast
06.12 Generic Drugs Market in Australia
06.12.1 Market Size and Forecast
06.13 Five Forces Analysis
07. Market Segmentation by Category
07.1 Global Generic Drugs Market by Category
07.1.1 Global Biosimilars Market
08. Market Segmentation by Therapeutic Applications
08.1 Global Generic Drugs Market by Therapeutic Applications
09. Geographical Segmentation
09.1 Global Generic Drugs Market by Geographical Segmentation
09.2 Generic Drugs Market in Americas
09.2.1 Market Size and Forecast
09.3 Generic Drugs Market in the EMEA Region
09.3.1 Market Size and Forecast
09.4 Generic Drugs Market in the APAC Region
09.4.1 Market Size and Forecast
10. Key Leading Countries
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Actavis plc
19.1.1 Business Overview
19.1.2 Business Segmentation
19.1.3 Key Information
19.1.4 SWOT Analysis
19.2 Mylan Inc.
19.2.1 Business Overview
19.2.2 Business Segmentation
19.2.3 Key Information
19.2.4 SWOT Analysis
19.3 Novartis International AG
19.3.1 Business Overview
19.3.2 Business Segmentation
19.3.3 Key Information
19.3.4 SWOT Analysis
19.4 STADA Arzneimittel AG
19.4.1 Business Overview
19.4.2 Business Segmentation
19.4.3 Key Information
19.5.1 SWOT Analysis
19.6 Teva Pharmaceutical Industries Ltd.
19.6.1 Business Overview
19.6.2 Business Segmentation
19.6.3 Key Information
19.6.4 SWOT Analysis
20. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Generic Drugs Market Overview
Exhibit 3: Global Generic Drugs Market 2013-2018 (US$ million)
Exhibit 4: Global Generic Drugs Market in the US 2013-2018 (US$ billion)
Exhibit 5: Global Generic Drugs Market in Europe 2013-2018 (US$ billion)
Exhibit 6: Generic Drugs Market in Europe Country Wise Market Share 2013
Exhibit 7: Generic Drugs Market in Germany 2013-2018 (US$ billion)
Exhibit 8: Generic Drugs Market in the UK 2013-2018 (US$ billion)
Exhibit 9: Generic Drugs Market in Italy 2013-2018 (US$ billion)
Exhibit 10: Generic Drugs Market in Italy 2013-2018 (US$ billion)
Exhibit 11: Generic Drugs Market in Spain 2013-2018 (US$ billion)
Exhibit 12: Generic Drugs Market in China 2013-2018 (US$ billion)
Exhibit 13: Generic Drugs Market in India 2013-2018 (US$ billion)
Exhibit 14: Generic Drugs Market in Australia 2013-2018 (US$ billion)
Exhibit 15: Global Generic Drugs Market Segmentation
Exhibit 16: Global Biosimilars Market 2013-2018 (US$ million)
Exhibit 17: Global Generic Drugs Market by Therapeutic Applications
Exhibit 18: Global Generic Drugs Market Segmentation by Therapeutic Applications 2013
Exhibit 19: Global Generic Drugs Market by Geographical Segmentation 2013
Exhibit 20: Global Generic Drugs Market in Americas 2013-2018 (US$ billion)
Exhibit 21: Global Generic Drugs Market in Europe 2013-2018 (US$ billion)
Exhibit 22: Generic Drugs Market in China 2013-2018 (US$ billion)
Exhibit 23: Global Generic Drugs Market by Geographical Segmentation 2013-2018 (in percentage)
Exhibit 24: YOY Growth Rate Comparison of the Geographic Segments in the Global Generic Drugs Market 2013-2018
Exhibit 25: Business Segmentation of Actavis plc
Exhibit 26: Business Segmentation of Mylan Inc.
Exhibit 27: Business Segmentation of Novartis International AG
Exhibit 28: Business Segmentation of STADA Arzneimittel AG
Exhibit 29: Business Segmentation of Teva Pharmaceutical Industries Ltd.